180 related articles for article (PubMed ID: 32343689)
1. A genome-wide enrichment screen identifies NUMA1-loss as a resistance mechanism against mitotic cell-death induced by BMI1 inhibition.
Gisler S; Maia ARR; Chandrasekaran G; Kopparam J; van Lohuizen M
PLoS One; 2020; 15(4):e0227592. PubMed ID: 32343689
[TBL] [Abstract][Full Text] [Related]
2. The BMI1 inhibitor PTC-209 is a potential compound to halt cellular growth in biliary tract cancer cells.
Mayr C; Wagner A; Loeffelberger M; Bruckner D; Jakab M; Berr F; Di Fazio P; Ocker M; Neureiter D; Pichler M; Kiesslich T
Oncotarget; 2016 Jan; 7(1):745-58. PubMed ID: 26623561
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of Bmi1 inhibits bladder cancer cell growth both in vitro and in vivo by blocking cell cycle at G1 phase and inducing apoptosis.
Luo HB; Li B; Yuan WG; Xu CR
J Huazhong Univ Sci Technolog Med Sci; 2015 Oct; 35(5):730-735. PubMed ID: 26489630
[TBL] [Abstract][Full Text] [Related]
4. Silencing of Bmi-1 gene enhances chemotherapy sensitivity in human glioblastoma cells.
Hong Y; Shang C; Xue YX; Liu YH
Med Sci Monit; 2015 Apr; 21():1002-7. PubMed ID: 25858624
[TBL] [Abstract][Full Text] [Related]
5. BMI1 activates WNT signaling in colon cancer by negatively regulating the WNT antagonist IDAX.
Yu F; Zhou C; Zeng H; Liu Y; Li S
Biochem Biophys Res Commun; 2018 Feb; 496(2):468-474. PubMed ID: 29337063
[TBL] [Abstract][Full Text] [Related]
6. Silencing BMI1 radiosensitizes human breast cancer cells by inducing DNA damage and autophagy.
Griffith J; Andrade D; Mehta M; Berry W; Benbrook DM; Aravindan N; Herman TS; Ramesh R; Munshi A
Oncol Rep; 2017 Apr; 37(4):2382-2390. PubMed ID: 28260023
[TBL] [Abstract][Full Text] [Related]
7. Bmi1 essentially mediates podocalyxin-enhanced Cisplatin chemoresistance in oral tongue squamous cell carcinoma.
Zhou Y; Zhang L; Pan H; Wang B; Yan F; Fang X; Munnee K; Tang Z
PLoS One; 2015; 10(4):e0123208. PubMed ID: 25915207
[TBL] [Abstract][Full Text] [Related]
8. Timosaponin A-III inhibits oncogenic phenotype via regulation of PcG protein BMI1 in breast cancer cells.
Gergely JE; Dorsey AE; Dimri GP; Dimri M
Mol Carcinog; 2018 Jul; 57(7):831-841. PubMed ID: 29528145
[TBL] [Abstract][Full Text] [Related]
9. Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing.
Zhao Q; Qian Q; Cao D; Yang J; Gui T; Shen K
J Ovarian Res; 2018 Apr; 11(1):31. PubMed ID: 29685168
[TBL] [Abstract][Full Text] [Related]
10. SPAG5: An Emerging Oncogene.
He J; Green AR; Li Y; Chan SYT; Liu DX
Trends Cancer; 2020 Jul; 6(7):543-547. PubMed ID: 32291236
[TBL] [Abstract][Full Text] [Related]
11. BMI1 Inhibitors Down-regulate NOTCH Signaling and Suppress Proliferation of Acute Leukemia Cells.
Ohtaka M; Itoh M; Tohda S
Anticancer Res; 2017 Nov; 37(11):6047-6053. PubMed ID: 29061784
[TBL] [Abstract][Full Text] [Related]
12. Polycomb complex protein BMI1 confers resistance to tamoxifen in estrogen receptor positive breast cancer.
Ojo D; Lin X; Wu Y; Cockburn J; Bane A; Tang D
Cancer Lett; 2018 Jul; 426():4-13. PubMed ID: 29626519
[TBL] [Abstract][Full Text] [Related]
13. BMI1 activates P-glycoprotein via transcription repression of
Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
[TBL] [Abstract][Full Text] [Related]
14. Validation of Bmi1 as a therapeutic target of hepatocellular carcinoma in mice.
Qi S; Li B; Yang T; Liu Y; Cao S; He X; Zhang P; Li L; Xu C
Int J Mol Sci; 2014 Nov; 15(11):20004-21. PubMed ID: 25372945
[TBL] [Abstract][Full Text] [Related]
15. Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells.
Zhu D; Wan X; Huang H; Chen X; Liang W; Zhao F; Lin T; Han J; Xie W
Oncol Rep; 2014 Feb; 31(2):727-36. PubMed ID: 24337040
[TBL] [Abstract][Full Text] [Related]
16. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
17. MDR1 mediated chemoresistance: BMI1 and TIP60 in action.
Banerjee Mustafi S; Chakraborty PK; Naz S; Dwivedi SK; Street M; Basak R; Yang D; Ding K; Mukherjee P; Bhattacharya R
Biochim Biophys Acta; 2016 Aug; 1859(8):983-93. PubMed ID: 27295567
[TBL] [Abstract][Full Text] [Related]
18. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma.
Teshima K; Nara M; Watanabe A; Ito M; Ikeda S; Hatano Y; Oshima K; Seto M; Sawada K; Tagawa H
Oncogene; 2014 Apr; 33(17):2191-203. PubMed ID: 23686310
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation.
Srinivasan M; Bharali DJ; Sudha T; Khedr M; Guest I; Sell S; Glinsky GV; Mousa SA
Oncotarget; 2017 Jun; 8(24):38731-38742. PubMed ID: 28418883
[TBL] [Abstract][Full Text] [Related]
20. The inhibitory effect of human DEFA5 in growth of gastric cancer by targeting BMI1.
Wu Z; Ding Z; Cheng B; Cui Z
Cancer Sci; 2021 Mar; 112(3):1075-1083. PubMed ID: 33503272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
